Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer protein puzzle: scientists hunt for clues in tissue and blood

NCT ID NCT01647867

First seen Mar 17, 2026 · Last updated Jun 23, 2026 · Updated 19 times

Summary

This study examined Met receptor fragments in tissue and blood samples from 56 people with non-small cell lung cancer. Researchers used special lab tests to see which fragments are present and whether they are active. The goal was to learn more about the disease, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centre Hospitalier Régional et Universitaire

    Lille, 59 037, France

  • Oscar Lambret Center

    Lille, 59020, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help researchers better understand how Met receptor fragments relate to lung cancer, potentially guiding future treatments.

What could go wrong

This is an observational study with no treatment being tested. It is small (56 participants) and only looks at protein expression, so it may not lead to direct patient benefits.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.